Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
Find a doctor at The Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center or Johns Hopkins Community Physicians.
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Johns Hopkins Medicine
Media Relations and Public Affairs
Media Contact: Jeff Ventura
July 25, 2006
Johns Hopkins Center to Focus on HIV-linked Brain Disorders and Treatment
--Federal funding announced
Scientists at The Johns Hopkins University School of Medicine have launched a new, federally funded collaborative research unit to develop novel treatments for HIV-related memory and other cognitive disorders.
The research initiative at Hopkins is one of seven sites funded by the National Institute of Mental Health, whose goal is to study cognitive disorders linked to HIV/AIDS, or to conduct behavioral approaches to reduce HIV transmission.
While the incidence of HIV-related dementia has dropped by an estimated 40 to 50 percent in the United States thanks, in large part, to effective antiviral drug cocktails (HAART), evidence is mounting that these drugs may fail to completely protect HIV-positive people from memory and learning problems. In fact, studies from the Hopkins HIV neuroscience group have shown that about 30 percent of people on HAART have measurable cognitive dysfunction.
“The good news is that we have drugs that keep people with HIV and AIDS physically healthy for a much longer time than was possible just a decade ago,” said Justin C. McArthur, M.B.B.S., M.P.H., a professor of neurology, pathology and epidemiology at the Johns Hopkins School of Medicine. “The bad news is that the prevalence of cognitive problems seems to be on the rise as these individuals survive longer. We need to know why, and what we can do better.”
McArthur and his research team plan on using the NIMH’s $1.25 million first- year grant to investigate why there are still no effective treatments specifically targeted at HIV dementia. “Oxidative stress,” the accumulation of toxic forms of oxygen, is the major focus of Hopkins’ research for new drugs. It has been clearly demonstrated that oxidative stress plays a major role in many neurological disorders, including aging, stroke and dementia.
The Hopkins center will also attempt to design and promote the wider use of more sensitive screening techniques for HIV dementia and develop novel surrogate markers of disease activity and progression. It will also stimulate new research by funding pilot grants designed to attract new researchers into the field. New techniques for the improved postgraduate education of medical providers in the neurological manifestations of HIV/AIDS will also be organized through the center.
McArthur will co-direct the center with investigators Joseph Steiner, Ph.D., and Avindra Nath, M.D. Other members of the Johns Hopkins research team will include Ned Sacktor, M.D., Min Li, Ph.D., Norman Haughey, Ph.D., Scott Zeger, Ph.D., Richard Moore, M.D., John Bartlett, M.D., Robert Cotter, Ph.D., Robert Cole, Ph.D., Wenxue Li, Ph.D., and Chris Zink, Ph.D. The center will also have an advisory council that will include several other prominent figures from the Johns Hopkins School of Medicine community, including Richard Johnson, former chair of the Department of Neurology; Sol Snyder, M.D., former chair of the Department of Neuroscience; Jeffrey Rothstein, M.D., a professor of neurology; and Chi Dang, M.D., vice dean for research.